CLINICAL_TRIALS
trial_result
· 2021-06-25
Clinical Trial Update: Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab [Phase 2]
Summary
Phase 2 study evaluating danicopan in PNH patients with inadequate response to eculizumab has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Status: COMPLETED | Results posted: 2021-06-25